Effects of K-115, a Rho-kinase inhibitor, on aqueous humor dynamics in rabbits

Current Eye Research

Volumn 39, Issue 8, 2014, Pages 813-822

  Isobe, Tomoyuki ^a   Mizuno, Ken ^a   Kaneko, Yoshio ^a   Ohta, Masayuki ^a   Koide, Takashi ^a   Tanabe, Sohei ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Aqueous humor dynamics; Glaucoma; Intraocular pressure; K 115; ROCK

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANTIHYPERTENSIVE AGENT; CARBON 14; FASUDIL; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INDOMETACIN; K 115; LATANOPROST; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; EYE DROPS; ISOQUINOLINE DERIVATIVE; K-115; RHO KINASE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR FLOW; ARTICLE; AUTORADIOGRAPHY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FLUOROPHOTOMETRY; INFLAMMATION; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; ANIMAL; ANTAGONISTS AND INHIBITORS; AQUEOUS HUMOR; DISEASE MODEL; DRUG EFFECTS; FOLLOW UP; GLAUCOMA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT;

ANIMALS; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; FLUOROPHOTOMETRY; FOLLOW-UP STUDIES; GLAUCOMA; INTRAOCULAR PRESSURE; ISOQUINOLINES; MALE; OPHTHALMIC SOLUTIONS; RABBITS; RHO-ASSOCIATED KINASES; SULFONAMIDES;

EID: 84904348321     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.874444     Document Type: Article

References (33)

1. Quigley HA. Open-angle glaucoma. N Engl J Med 1993; 328:1097-1106.
2. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 2004;111: 1641-1648.
3. Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol 2008;19:85-88.
4. Bahrami H. Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure. Ophthalmic Epidemiol 2006;13:283-289.
5. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-456.
6. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005;33:891-895.
7. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994.
8. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008;20:242-248.
9. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs 2007;21:167-177.
10. Nakajima E, Nakajima T, Minagawa Y, Shearer TR, Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005;94: 701-708.
11. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;42:137-144.
12. Waki M, Yoshida Y, Oka T, Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-474.
13. Honjo M, Inatani M, Kido N, Sawamura T, Yue BY, Honda Y, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 2001;119:1171-1178.
14. Tamura M, Nakao H, Yoshizaki H, Shiratsuchi M, Shigyo H, Yamada H, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochimica et Biophysica Acta 2005;1754:245-252.
15. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007;48:3216-3222.
16. Tanihara H, Abe H, Kuwayama Y, Yamamoto T, Araie M. Ocular hypotensive dose-response efficacy and safety of the rho kinase inhibitor, K-115, in patients with primary open-angle glaucoma and ocular hypertension. IOVS 2011;52:ARVO E-Abstract 220.
17. Yamamoto T, Abe H, Kuwayama Y, Tanihara H, Araie M. Efficacy and safety of the rho kinase inhibitor, K-115, over 24 hours in patients with primary open-angle glaucoma and ocular hypertension. IOVS. 2011;52:ARVO E-Abstract 216.
18. Kanno M, Araie M, Tomita K, Sawanobori K. Effects of topical Nipradilol, a, b-blocking agent with a-blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation. Invest Ophthalmol Vis Sci 1998;39: 736-743.
19. Suguro K, Toris CB, Pederson JE. Uveoscleral outflow following cyclodialysis in the monkey eye using a fluorescent tracer. Invest Ophthalmol Vis Sci 1985;26: 810-813.
20. Goh Y, Araie M, Nakajima M, Azuma I, Hayaishi O. Effect of topical prostaglandin D2 on the aqueous humor dynamics in rabbits. Graefes Arch Clin Exp Ophthalmol 1989;227:476-481.
21. Mizuno K. Ocular hypotensive mechanism of a-, b-blocker (Nipradilol ophthalmic solution). Atarashii Ganka (J Eye) 1999;16:529-535. (in Japanese).
22. Barany EH. Simultaneous measurement of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure perfusion. Invest Ophthalmol Vis Sci 1964;3:135-143.
23. Taniguchi T, Okada K, Haque MS, Sugiyama K, Kitazawa Y. Effects of endothelin-1 on intraocular pressure and aqueous humor dynamics in the rabbit eye. Curr Eye Res 1994;13:461-464.
24. Ono-Saito N, Niki I, Hidaka H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol Ther 1999;82:123-131.
25. Hidaka H, Kobayashi R. Pharmacology of protein kinase inhibitors. Annu Rev Pharmacol Toxicol 1992;32:377-397.
26. Asano T, Suzuki T, Tsuchiya M, Satoh S, Ikegaki I, Shibuya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 1989;98:1091-1100.
27. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984;23:5036-5041.
28. Whitlock NA, Harrison B, Mixon T, Yu XQ, Wilson A, Gerhardt B, et al. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK. J Ocul Pharmacol Ther 2009;25:187-194.
29. Zamora DO, Kiel JW. Topical proparacaine and episcleral venous pressure in the rabbit. Invest Ophthalmol Vis Sci 2009;50:2949-2952.
30. Nishimura K, Kuwayama Y, Matsugi T, Sun N, Shirasawa E. Selective suppression by bunazosin of alpha-adrenergic agonist evoked elevation of intraocular pressure in sympathectomized rabbit eyes. Invest Ophthalmol Vis Sci 1993;34:1761-1766.
31. Hosoya K, Lee VH, Kim KJ. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 2005;60:227-240.
32. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, editor. Pharmacology of the eye. Berlin: Springer-Verlag; 1984. pp 19-116.
33. Koga T, Koga T, Awai M, Tsutsui J, Yue BY, Tanihara H. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res 2006;82:362-370.